Browsing by Subject "transforming growth factor beta1"

Now showing items 1-4 of 4

    • Article  

      Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels 

      Chauhan, V. P.; Martin, J. D.; Liu, H.; Lacorre, D. A.; Jain, S. R.; Kozin, S. V.; Stylianopoulos, T.; Mousa, A. S.; Han, X.; Adstamongkonkul, P.; Popovic, Z.; Huang, P.; Bawendi, M. G.; Boucher, Y.; Jain, R. K. (2013)
      Cancer and stromal cells actively exert physical forces (solid stress) to compress tumour blood vessels, thus reducing vascular perfusion. Tumour interstitial matrix also contributes to solid stress, with hyaluronan ...
    • Article  

      Pirfenidone normalizes the tumor microenvironment to improve chemotherapy 

      Polydorou, C.; Mpekris, F.; Papageorgis, P.; Voutouri, C.; Stylianopoulos, T. (2017)
      Normalization of the tumor microenvironment by selectively targeting components of the tumor extracellular matrix has been recently proposed to have the potential to decompress tumor blood vessels, increase vessel perfusion ...
    • Article  

      Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1α-hydroxyvitamin D5 

      Mehta, R. G.; Moriarty, R. M.; Mehta, R. R.; Penmasta, R.; Lazzaro, G.; Constantinou, Andreas I.; Guo, L. (1997)
      Background: The form of vitamin D (vitamin D3) in fortified milk and the provitamin D produced by the body undergo metabolic activation to a biologically active form, 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D3]. This compound ...
    • Article  

      RAAS inhibition and the course of Alport syndrome 

      Savva, Isavella; Pierides, Alkis M.; Constantinou-Deltas, Constantinos D. (2016)
      Alport syndrome (AS) is a hereditary progressive glomerulonephritis with a high life-time risk for end-stage renal disease (ESRD). Most patients will reach ESRD before the age of 30 years, while a subset of them with milder ...